Free tool
FAERS Monitor: Finacea
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207071 or its brand name (Finacea, Azelaic Acid). Reports on generic versions are filed under their own applications.
Reports
848
Serious
450
53% of reports
Hospitalization
167
Death reported
84
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective154
- pain131
- off label use118
- abdominal pain upper112
- vomiting110
- product use in unapproved indication103
- gastrooesophageal reflux disease102
- paraesthesia102
- migraine101
- memory impairment99
- hypoaesthesia98
- rash97
- blepharospasm95
- taste disorder93
- drug intolerance91
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 5 |
| 2009 | 3 |
| 2010 | 8 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 6 |
| 2015 | 20 |
| 2016 | 17 |
| 2017 | 14 |
| 2018 | 27 |
| 2019 | 30 |
| 2020 | 59 |
| 2021 | 68 |
| 2022 | 71 |
| 2023 | 86 |
| 2024 | 134 |
| 2025 | 139 |
| 2026 | 150 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,311 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blepharospasmSignal | 95 | 379.8 | 313.7 | 34,989 |
| taste disorderSignal | 93 | 114.2 | 94.2 | 10,287 |
| gastrooesophageal reflux diseaseSignal | 102 | 31.5 | 26.2 | 2,986 |
| migraineSignal | 101 | 26.3 | 21.9 | 2,438 |
| drug intoleranceSignal | 91 | 23.4 | 19.3 | 1,935 |
| memory impairmentSignal | 99 | 17.9 | 14.9 | 1,570 |
| hypoaesthesiaSignal | 98 | 16.2 | 13.5 | 1,396 |
| paraesthesiaSignal | 102 | 16.1 | 13.4 | 1,438 |
| abdominal pain upperSignal | 112 | 13.5 | 11.4 | 1,296 |
| product use in unapproved indicationSignal | 103 | 10.3 | 8.6 | 867 |
| vomitingSignal | 110 | 5.8 | 4.9 | 442 |
| rashSignal | 97 | 5.5 | 4.6 | 362 |
| painSignal | 131 | 5.3 | 4.5 | 465 |
| off label useSignal | 118 | 3.3 | 2.8 | 200 |
| drug ineffectiveSignal | 154 | 2.9 | 2.5 | 202 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.